RecruitingNCT06409013
Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma
Sarcoma Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography
Sponsor
Mayo Clinic
Enrollment
75 participants
Start Date
Mar 14, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study evaluates the effectiveness of intraoperative indocyanine green dye and fluoroscopic technology in confirming negative margins after tumor removal.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study tests whether a special fluorescent dye (indocyanine green, or ICG) used during surgery can help surgeons better see the edges of bone and soft tissue sarcomas (rare cancers of bones and connective tissue) to ensure they remove the entire tumor.
**You may be eligible if...**
- You have been diagnosed with bone or soft tissue sarcoma confirmed by biopsy
- You are 18 years or older
- You are scheduled for surgery to remove the tumor
**You may NOT be eligible if...**
- You are under 18 years old
- You have chronic kidney disease
- You have had a severe allergic reaction to dyes or contrast agents in the past
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06409013
Related Trials
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
NCT045770141 location
Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma
NCT0430727719 locations
Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention
NCT07662239
Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
NCT07514819
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
NCT072837311 location